Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy

Yamagiwa, Yoko; Asano, Mai; Kawasaki, Youhei; Korenaga, Masaaki; Murata, Kazumoto; Kanto, Tatsuya; Mizokami, Masashi; Masaki, Naohiko

doi:10.1016/j.cyto.2016.07.004

Cited by 2 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A paper by Yamagiwa et al investigated the importance of pretreatment serum CXCL10 levels and IL-28B genotyping in predicting SVR to TVR-based triple therapy in patients with HCV 1 genotype [118]. The median CXCL10 levels were significantly lower in rapid virologic response (RVR) (343 pg/mL in RVR vs. 593 pg/mL in non-RVR patients, P < 0.01) or SVR (359 pg/mL in SVR vs. 566 pg/mL in non-SVR patients, P < 0.05) in the IL-28B non-TT genotype group.…”

Section: Hcv Therapy and Cxcl10mentioning

confidence: 99%

“…SVR rates in the group with lower CXCL10 levels (<450 pg/mL) raised to 82% for those showing RVR, but decreased to 27% in the group with higher CXCL10 levels for those not showing RVR. The paper showed that the determination of serum CXCL10 levels before treatment could be useful to predict an effective virologic response to TVR-based triple therapy, particularly in patients with IL-28B non-TT genotype [118].…”

Section: Hcv Therapy and Cxcl10mentioning

confidence: 99%

See 1 more Smart Citation

Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?

Ferrari

Fallahi

Ruffilli

et al. 2019

Journal of Immunology Research

View full text Add to dashboard Cite

Chemokine (C-X-C motif) ligand (CXCL)10 and other CXCR3 chemokines are involved in the pathogenesis of acute and “chronic hepatitis C virus (HCV) infection” (CHC). Here, we review the scientific literature about HCV and CXCL10. The combination of circulating CXCL10 and single nucleotide polymorphisms (SNPs) in IL-28B can identify patients with acute HCV infection most likely to undergo spontaneous HCV clearance and those in need of early antiviral therapy. In CHC, the HCV and intrahepatic interferon- (IFN-) γ drive a raised CXCL10 expression by sinusoidal endothelium and hepatocytes, thereby inducing the recruitment of CXCR3-expressing T cells into the liver; thus, CXCL10 plays an important role in the development of necroinflammation and fibrosis. Increased CXCL10 was significantly associated with the presence of active vasculitis in HCV-associated cryoglobulinemia, or with autoimmune thyroiditis in CHC. Pretreatment CXCL10 levels are predictive of early virological response and sustained virological response (SVR) to IFN-α and ribavirin and may be useful in the evaluation of candidates for therapy. The occurrence of SNPs adjacent to IL-28B (rs12979860, rs12980275, and rs8099917), and CXCL10 below 150 pg/mL, independently predicted the first phase viral decline and rapid virological response, which in turn independently predicted SVR. Directly acting antiviral agents-mediated clearance of HCV is associated with the loss of intrahepatic immune activation by IFN-α, associated by decreased levels of CXCL10. In conclusion, CXCL10 is an important marker of HCV clearance and successful therapy in CHC patients. Whether CXCL10 is a novel therapeutic target in CHC will be evaluated.

show abstract

Section: Hcv Therapy and Cxcl10mentioning

confidence: 99%

Section: Hcv Therapy and Cxcl10mentioning

confidence: 99%

Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?

Ferrari

Fallahi

Ruffilli

et al. 2019

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…IP-10 has also been implicated in inflammatory diseases (93) and in numerous autoimmune diseases (94). Blood IP-10 concentrations have been proposed as a biomarker of disease activity that predicts response to treatment for TB, HIV and hepatitis C, where patients with lower IP-10 showed a more rapid virologic response and intracellular infections are controlled better or cleared faster in the absence of IL-10 (95). Other researchers have shown that treatment response to hepatitis B and C is independently associated with IP-10 polymorphisms (96, 97).…”

Section: Discussionmentioning

confidence: 99%

Discriminatory cytokine profiles predict muscle function, fatigue and cognitive function in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Gusnanto

Earl

Sakellariou

et al. 2020

Preprint

View full text Add to dashboard Cite

Myalgic Encephalomyelitis (ME) /Chronic Fatigue Syndrome (CFS) is a severely debilitating and complex illness of uncertain aetiology, affecting the lives of millions and characterised by prolonged fatigue. The initiating factors and mechanisms leading to chronic debilitating muscle fatigue in ME/CFS are unknown and are complicated by the time required for diagnosis. Both mitochondrial dysfunction and inflammation have been proposed to be central to the pathogenesis of ME/CFS. This original and extensive study demonstrated that although there was little dysfunction evident in the muscle mitochondria of patients with ME/CFS, particular blood plasma and skeletal muscle cytokines, when adjusted for age, gender and cytokine interactions could predict both diagnosis and a number of measures common to patients with ME/CFS. These included MVC and perceived fatigue as well as cognitive indices such as pattern and verbal reaction times. We employed advanced multivariate analyses to cytokine profiles that leverages covariation and intrinsic redundancy to identify patterns of immune signaling that can be evaluated for their predictions of disease phenotype. The current study identified discriminatory cytokine profiles that can be sufficiently used to distinguish HCs from patients with ME/CFS and provides compelling evidence that a limited number of cytokines are associated with diagnosis and fatigue. Moreover, this study demonstrates significant potential of using multiplex cytokine profiles and bioinformatics as diagnostic tools for ME/CFS, potentiating the possibility of not only diagnosis, but also being able to individually personalise therapies.

show abstract

Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy

Cited by 2 publications

References 40 publications

Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?

Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?

Discriminatory cytokine profiles predict muscle function, fatigue and cognitive function in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Contact Info

Product

Resources

About